FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2124096932> ?p ?o ?g. }

• W2124096932 abstract "A double blinded placebo controlled clinical trial of a commercial digoxin immune Fab fragment (DIF) in preeclamptic (PE) women provided some benefit to treated subjects (1). In that study DIF, relative to placebo, prevented a decline in CrCl and lowered levels of endogenous digitalis-like factor (EDLF) activity as measured by sodium pump inhibition (SPI). However, some PE subjects had undetectable EDLF.The hypothesis tested was that only PE women with measureable EDLF would respond to DIF treatment and analysis of EDLF positive women might reveal treatment effects masked by inclusion of EDLF negative, and hence non-responding, PE women. Accordingly, analyses of DIF effects in EDLF positive PE women were conducted.Patient characteristics and study design have been published (1). In these subanalyses, subjects were considered to be EDLF positive if their plasma inhibited red cell sodium pump mediated Rb uptake. All analyses were redone for the EDLF positive subgroup by Covance Inc as in the original trial. Continuous data were analyzed by ANCOVA. Categorical data were analyzed by Barnard Exact Test.45 subjects (23 DIF, 22 placebo) had baseline SPI evaluated. Of these 22% had undetectable SPI. EDLF positive PE women showed greater and more significant reductions of SPI in response to DIF at each time point (12, 24, 48 hr treatment) than in the original analysis. Subjects with undetectable EDLF showed no significant change in response to DIF or placebo. For CrCl, EDLF positive PE women showed greater and more significant preservation of CrCl compared with original analyses. Subjects absent EDLF showed deterioration of CrCl with or without DIF. Among EDLF positive PE women DIF treated women had significantly less maternal pulmonary edema (p=0.035) and significantly less intraventricular hemorrhage in their infants (p=0.015). There was the suggestion of reductions in the incidence of other maternal and neonatal abnormalities.These data indicate that EDLF positive PE women are those that responded to DIF and also raise the possibility of extended benefits of DIF treatment in this group. Results support further research in this area." @default.
• W2124096932 created "2016-06-24" @default.
• W2124096932 creator A5012228293 @default.
• W2124096932 creator A5017272665 @default.
• W2124096932 creator A5036803581 @default.
• W2124096932 creator A5048554415 @default.
• W2124096932 creator A5063732558 @default.
• W2124096932 creator A5074870344 @default.
• W2124096932 creator A5080584791 @default.
• W2124096932 date "2012-07-01" @default.
• W2124096932 modified "2023-09-27" @default.
• W2124096932 title "PP087. Deep trial secondary analysis: Digoxin immune fab fragment treatment has additional benefits in endogenous digitalis-like factor positive preeclamptic women" @default.
• W2124096932 doi "https://doi.org/10.1016/j.preghy.2012.04.198" @default.
• W2124096932 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26105409" @default.
• W2124096932 hasPublicationYear "2012" @default.
• W2124096932 type Work @default.
• W2124096932 sameAs 2124096932 @default.
• W2124096932 citedByCount "1" @default.
• W2124096932 countsByYear W21240969322013 @default.
• W2124096932 crossrefType "journal-article" @default.
• W2124096932 hasAuthorship W2124096932A5012228293 @default.
• W2124096932 hasAuthorship W2124096932A5017272665 @default.
• W2124096932 hasAuthorship W2124096932A5036803581 @default.
• W2124096932 hasAuthorship W2124096932A5048554415 @default.
• W2124096932 hasAuthorship W2124096932A5063732558 @default.
• W2124096932 hasAuthorship W2124096932A5074870344 @default.
• W2124096932 hasAuthorship W2124096932A5080584791 @default.
• W2124096932 hasConcept C126322002 @default.
• W2124096932 hasConcept C142724271 @default.
• W2124096932 hasConcept C204787440 @default.
• W2124096932 hasConcept C27081682 @default.
• W2124096932 hasConcept C2777707475 @default.
• W2124096932 hasConcept C2778198053 @default.
• W2124096932 hasConcept C71924100 @default.
• W2124096932 hasConceptScore W2124096932C126322002 @default.
• W2124096932 hasConceptScore W2124096932C142724271 @default.
• W2124096932 hasConceptScore W2124096932C204787440 @default.
• W2124096932 hasConceptScore W2124096932C27081682 @default.
• W2124096932 hasConceptScore W2124096932C2777707475 @default.
• W2124096932 hasConceptScore W2124096932C2778198053 @default.
• W2124096932 hasConceptScore W2124096932C71924100 @default.
• W2124096932 hasLocation W21240969321 @default.
• W2124096932 hasLocation W21240969322 @default.
• W2124096932 hasOpenAccess W2124096932 @default.
• W2124096932 hasPrimaryLocation W21240969321 @default.
• W2124096932 isParatext "false" @default.
• W2124096932 isRetracted "false" @default.
• W2124096932 magId "2124096932" @default.
• W2124096932 workType "article" @default.